View Older Stories View More Recent Stories
-
Streetinsider.com's Hot Lunchtime Reads 7/28: (TWTR) (MU) (MGM) (ESPR)
-
Lower Taxes, Strong Buybacks Push Plantronics (PLT) to Q1 'Beat' - Roth Capital
-
Consumer Electronics Giant VIZIO, Inc., Files for $172.5M Common Stock IPO
-
Roth Capital Cuts Price Target on BioLineRx (BLRX) to $7 Following Data Results
-
Roth Capital Raises Price Target to $18 on Celator Pharmaceuticals (CPXX) Seeing Share Price Disconnect
-
Regeneron (REGN) Investors Already Pricing-in Praluent Approval; Roth Capital Affirms at 'Neutral'
-
Roth Capital Starts Unique Fabricating (UFAB) at Buy
-
Roth Capital Cuts Price Target on Iconix Brand Group (ICON) to $28 Ahead of 2Q15
-
VIZIO Files Registration Statement for Initial Public Offering of Class A Common Stock
-
Roth Capital Remains Bullish on Ligand Pharma (LGND) Following FDA Approval of Kyprolis sNDA (AMGN)
-
Roth Affirms Keryx Biopharma (KERX) at 'Buy'; CHMP Opinion on Fexeric Not Unexpected
-
Roth Capital Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Sell, $1 PT
-
Roth Capital Upgrades IGI Laboratories (IG) to Buy; Sees 2016 at Break-Out Year
-
UPDATE: Keryx Biopharmaceuticals (KERX) PT Cut to $11 at Roth Capital; Auryxia In Major 'Show Me' Phase
-
Notable 52-Week Highs and Lows 7/22: (EXEL) (DVAX) (ABT) High; (XOMA) (CZR) (BEAV) Low
-
Unusual 11 Mid-Day Movers 7/22: (SLTD) (LPCN) (BZUN) Higher; (XOMA) (ANGI) (CZR) Lower
-
Notable Analyst Rating Changes 7/22: (AMZN) (AUY) (JCP) Upgraded; (ABG) (UTC) (CHK) Downgraded
-
RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares
-
Pre-Open Stock Movers 07/22: (ISRG) (THOR) (EYES) Higher; (XOMA) (ILMN) (AAPL) Lower (more...)
-
Roth Capital Raises Price Target on Neogen Corp (NEOG) Following 4Q15 Results
-
Roth Capital Starts Lipocine Inc (LPCN) at Buy, $36 PT
-
Roth Capital Starts Pieris Pharmaceuticals (PIRS) at Buy
-
NeuroDerm Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
NeuroDerm Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Roth Affirms Ligand Pharma (LGND) at 'Buy'; Promacta Q2 Revenue Outpaces Expectations (NVS)
-
4th Annual Gateway Conference to Showcase More Than 80 Growth Companies in San Francisco on September 9-10
-
ROTH Capital Partners Expands Healthcare Banking Practice with Addition of Adam Stormoen as a Director, Investment Banking
-
Cempra (CEMP) PT Raised to $56 at Roth Capital; Solithromycin Positioned to Eclipse Macrolides in COPD
-
Tonix Pharmaceuticals Closes $20.1 Million Public Offering of Common Stock
-
Vermillion, Inc. Announces Closing of $18.8 Million Public Offering of Common Stock
-
Iconix Investors: Lieff Cabraser Reminds Investors of Upcoming Deadline in Class Action Litigation - ICON
-
Roth Capital Starts Global Water Resources (GWGWF) at Buy
-
Roth Capital Downgrades Golden Minerals Company (AUMN) to Neutral
-
RedHill Biopharma (RDHL) Prices 2.46M Public Offering at $16.25/ADS
-
RedHill Biopharma Prices Public Offering of Its American Depository Shares
-
Delcath Systems (DCTH) Prices 9.35M Public Offering at $0.75/Unit
-
Delcath Announces Pricing Of Public Offering
-
Roth Capital Raises the Price Target on Middleby Corp (MIDD) Ahead of AGA Rangemaster Acquisition
-
Roth Capital Sees Compelling Entry Point in uniQure BV (QURE) Ahead of Data Readouts
-
MEDIGUS ANNOUNCES COMPLETION OF $7.1 MILLION PUBLIC OFFERING
-
MEDIGUS ANNOUNCES COMPLETION OF $7.1 MILLION PUBLIC OFFERING
-
NeuroDerm Ltd. Announces Pricing of Public Offering
-
NeuroDerm Ltd. Announces Pricing of Public Offering
-
Streetinsider.com's Hot Lunchtime Reads 7/15: (M) (BLRX) (ARCP) (TBT)
-
BioLineRx (BLRX) Bullish Stance Reiterated at Roth Capital Ahead of Data Release
-
RedHill Biopharma (RDHL) to Offer 1.8M ADSs
-
RedHill Biopharma Announces Size of Proposed Public Offering of Its American Depository Shares
-
ANI Pharmaceuticals (ANIP) PT Bumped to $70 at Roth Capital
-
Macrogenics (MGNX) Prices Larger 3.53M Common Stock Offering at $37/Share
-
MacroGenics Announces Pricing of Public Offering of Common Stock

